ViroPharma Inc  (VPHM) Trade Now »     Rate VPHM  -  Discuss VPHM  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

VPHM Analysis & Videos »


VPHM: Bull or Bear?

FDA Calendar Updates: MELA, PGNX, VPHM, WYE VPHM

73%

+8.32% in 122 days <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  08/05/09

Comment

A New Global Healthcare Composite Index VPHM

73%

-41.80% in 204 days (closed on 08/05/09) A New Global Healthcare Composite Index <> The accompanying table [click to enlarge] presents the top five rated companies with market caps of at least $100M from each of the eight new ETF Innovators healthcare indexes, including a database exceeding 500 companies worldwide. The Healthcare Composite Index is a dynamic, semi-active index with quarterly rebalancing which consists of the 40 top-rated companies on an equal weight basis from each of the eight global healthcare indexes listed below and represents an alternative strategy to existing health composite ETF... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/13/09

Comment

A New Index of Health Product Innovators VPHM

73%

-6.57% in 8 days (closed on 01/13/09) A New Index of Health Product Innovators <> The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  01/05/09

Comment

FDA Calendar: A Weekly Update VPHM

73%

+15.13% in 30 days (closed on 01/05/09) FDA Calendar: A Weekly Update <> The accompanying table [click to enlarge] presents an updated calendar of 73 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week. 1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standa< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  12/05/08

Comment

ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? VPHM

73%

+7.69% in 23 days (closed on 12/05/08) ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? <> <> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/12/08

Comment

ViroPharma Value Worth Buying VPHM

-24.65% in 528 days ViroPharma could be a dramatically different-looking company in 2010 if pipeline antiviral candidate Camvia succeeds in treating cytomegalovirus disease. Continue reading »

By  Zacks.com   (-12.96%  risk: moderate)  06/24/08

Comment

ViroPharma: Cheap Cheap Cheap VPHM

11%

-12.28% in 686 days This company has great cash flow, a great product line, very profitable and is frankly in the right spot at the right time.  A primary focus is antibiotic resistant strep (a growing concern in the US).  The company has a P/E of 7.5 which more than qualifies it as a value stock.  Recently this stock has been talked about by several small cap managers on CNBC and Bloomberg showing that it is finally starting to be noticed.  Disclosure: I do not hold this stock personally but several of my client do. Continue reading »

By  Mike   (-32.82%  risk: moderate)  01/18/08

Comment

Camvia & Vancocin & The Baker Brothers VPHM

27%

+1.13% in 754 days Reasons to buy: 1. Baker Brothers bought 900,000 shares on Nov 8,2007  2. Camvia Phase III trials could be very promising with FDA Orphan status 3. Possible increase in demand for Vancocin even with generic due out in 2008?    Continue reading »

By  Bill German   (-33.79%  risk: aggressive)  11/11/07

Comment

VPHM has a good tone to it in early trading today VPHM

-47.97% in 1045 days ViroPharma Inc. has a good tone to it in early trading today so keep this stock on that trading radar. Continue reading »

By  visualtrader.blogspot.com   (-40.41%  risk: aggressive)  01/24/07

Comment

People Bullish on VPHM

Mike Havrilla Principal 73% 4 mos ago	mrinal Analyst N/A 4 mos ago	roby1050 Analyst N/A 4 mos ago
seismicstock Principal 70% 4 mos ago	gastate Analyst N/A 5 mos ago

People Bearish on VPHM

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.